Trovagene (NASDAQ:TROV) reported new positive data from its Phase 2 trial of onvansertib in combination with Zytiga in patients with metastatic castration-resistant prostate cancer (mCRPC).
The study’s primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks, as defined by lack of prostate specific antigen (PSA) progression.
Patients who were evaluable for efficacy demonstrated a 60% response rate, with 72% of patients exhibiting a decrease in PSA following one cycle of onvansertib.
Five patients tested positive for the highly aggressive, resistant variant of the androgen receptor. Following one cycle of onvansertib, all five had decreases in PSA and three out of four evaluable patients achieved the primary efficacy endpoint.
“The new data shared today builds upon the encouraging clinical response seen to date when onvansertib is added to treatment in patients who have developed resistance to androgen receptor signaling (ARS) inhibitor, Zytiga,” CSO Dr. Mark Erlander said in a statement.
“We believe the addition of onvansertib has the potential to deliver transformative benefit to patients with mCRPC by extending the duration of response to treatment with ARS inhibitors,” he added.
